TNFRSF11B/OPG 蛋白, Human (HEK293, His, solution)

Osteoprotegerin (OPG), a TNF receptor superfamily, is expressed in many tissues including heart, kidney, liver, spleen, and bone marrow. Osteoprotegerin has osteoprotective effect and is critical in bone remodeling. Osteoprotegerin can bind to RANKL and inhibit the binding between TNFSF11 and RANKL, thereby neutralizing the RANKL function in osteoclastogenesis^[1]. OPG is also involved in multiple biological processes of cancers. TNFRSF11B/OPG Protein, Human (HEK293, His, solution) is a recombinant human TNFRSF11B/OPG (E22-L401) with C-terminal His tag, which is produced in HEK293 cell^[1][2].

骨保护素（OPG）是一种糖蛋白，属于TNF受体超家族。OPG 在除成骨细胞外的许多组织中表达，包括心脏、肾脏、肝脏、脾脏和骨髓。人骨保护素与小鼠和大鼠的氨基酸序列同一性<85%。小鼠 OX40 与大鼠^[1]有 94.5% aa 序列同一性。
骨保护素可以与 RANKL 结合，并抑制 TNFSF11 与 RANKL 之间的结合，从而中和 RANKL 在破骨细胞生成中的功能。骨保护素还可以保护大血管免受内侧钙化。骨保护素水平升高一直与冠状动脉疾病的发病率和患病率相关^[1][3]。骨保护素还参与癌症的多个过程，如肿瘤存活、上皮间质转化 (EMT)、新生血管生成、侵袭和转移^[2]。
骨保护素在癌症中发挥着关键作用参与骨重塑，并具有骨保护作用^[1]。

RANKL (human, -1 pg/mL, 36 h) promotes the proliferation of VSMC^[5].

Osteoprotegerin (human, 5 mg/kg, i.v.) shows antiresorptive effects in rats^[4].

Immobilized Osteoprotegerin Protein, Human, Recombinant (His Tag) at 2 μg/mL (100 μL/well) can bind RANKL Protein, Human, Recombinant (ECD, hFc Tag), the EC₅₀ is 13-64 ng/mL.

Human

HEK293

C-His

O00300 (E22-L401)

4982  [NCBI]

Approximately 55 kDa

Greater than 95% as determined by reducing SDS-PAGE

溶液.

Supplied as a 0.22 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

N/A.

Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.

Shipping with dry ice.

• [1]. Boyce BF, et al. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9 Suppl 1(Suppl 1):S1.  [Content Brief]

  [2]. Wang Y, et al. The roles of osteoprotegerin in cancer, far beyond a bone player. Cell Death Discov. 2022 May 6;8(1):252.  [Content Brief]

  [3]. Venuraju SM, et al. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010 May 11;55(19):2049-61.  [Content Brief]

  [4]. Capparelli C, et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res. 2003 May;18(5):852-8.  [Content Brief]

  [5]. Candido R, et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res. 2010;47(3):252-61.  [Content Brief]